#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dedifferentiated liposarcoma Retinal dystrophy Vulval cancer Restless legs syndrome Mantle cell lymphoma refractory Scleroderma associated digital ulcer Mucopolysaccharidosis I Orthostatic hypotension Wolfram syndrome Dupuytren's contracture Rosai-Dorfman syndrome Hereditary hypophosphataemic rickets Primary mediastinal large B-cell lymphoma Hypertriglyceridaemia Infective uveitis More trials…

    Learn about Rare Diseases

    Pelizaeus-Merzbacher disease – Basic Information Kearns-Sayre syndrome – Basic Information Adrenocortical carcinoma – Diagnostics Gastrointestinal stromal tumour – Diagnostics Alternating hemiplegia of childhood – Life with Disease Alport’s syndrome – Basic Information Niemann-Pick disease – Basic Information Hereditary motor and sensory neuropathy – Diagnostics VEXAS syndrome Propionic acidaemia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VTX-002 Clenbuterol Hydrochloride 2,4 DICHLOROBENZYL ALCOHOL Clemizole Hydrochloride Desflurane Clemastine Fumarate Trientine Dihydrochloride Clemastine Celecoxib Mps-215 PARECOXIB Ammonium Chloride Domperidone Sulfur Hexafluoride Tebipenem Pivoxil Hydrobromide LYSERGIDE GSKVX000000046019 Plerixafor Atorvastatin Calcium Tafluprost More therapies…

    Learn about Your Condition

    HER2 positive gastric cancer Embolism venous Tumour of ampulla of Vater Basal cell naevus syndrome Vulval cancer Carpal tunnel syndrome Type IIa hyperlipidaemia Thalassaemia Pharyngeal cancer stage II Demyelination Apathy Apheresis Thymoma Electrocorticogram Complicated appendicitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Divarasib
    • Nivolumab
    • Pembrolizumab
    Austria Belgium France Germany Greece Ireland +5

  • Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Siltuximab
    • Tarlatamab
    Belgium France Germany Greece Hungary Italy +5

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ampicillin Sodium
    • POLYMYXIN B SULFATE
    • Rifabutin
    Croatia Greece

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • Metronidazole, Bismuth Oxide and Tetracycline Hydrochloride Fixed‑Dose Combination vs Standard First‑line Therapy for Adults with Helicobacter pylori Infection

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amoxicillin
    • Clarithromycin
    • Esomeprazole
    Greece

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9
1 2 3 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!